Navigation Links
ImQuest Presentations at CROI Report Significant Advances in Therapeutic and Microbicide Product Development Programs

FREDERICK, Md., Feb. 20 /PRNewswire/ -- ImQuest Life Sciences presented important new results on the continued development of their small molecule pyrimidinedione inhibitors of HIV-1 at the 16th Conference on Retroviruses and Opportunistic Infections held last week in Montreal. Presentations focused on the results of IND-directed development of the HIV therapeutic IQP-0410 and the efficacy and formulation of IQP-0528 as a topical microbicide to prevent the sexual transmission of HIV. The pyrimidinediones are highly potent inhibitors of HIV, exhibiting a novel dual mechanism of action which includes targeting virus entry and reverse transcription, a highly positive safety profile, and enhanced sensitivity against multi-drug resistant viruses isolated from patients. For prevention, the lead pyrimidinedione exhibits characteristics of an ideal microbicide, including the inhibition of two early steps in the viral replication pathway as well as its lack of toxicity to the cells and normal bacterial flora of the vaginal microenvironment.

Nick Kaludov, Ph.D. (Director, Product Development) and Todd B. Parsley, Ph.D. (Director, Molecular Virology) presented data on the IQP-0410 development programs which demonstrate the potential for oral, once per day dosing of IQP-0410. The highly attractive safety profile, ability of the compound to positively interact in combination with other HIV drugs, and the high intrinsic genetic barrier to resistance of the clinical candidate, was emphasized in these presentations. ImQuest, in collaboration with their drug development partner Samjin Pharmaceutical Co. Ltd of Seoul, Korea, have recently engaged in an effort to develop more active pyrimidinediones possessing this higher genetic barrier to resistance. It is believed that these compounds will prolong the therapeutic utility of the pyrimidinediones by preventing HIV from easily evading the action of the drug and will allow ImQuest to develop even more potent HIV inhibitors following the entry of IQP-0410 to Phase 1 human clinical trials in early 2009. These studies included ImQuest coauthors Robert W. Buckheit, Jr. (Executive Vice President), Robert Buckheit, III, Christa Buckheit, and Karen M. Watson.

Karen M. Watson, M.S. (Director, Topical Microbicide Research & Development) presented critical new information regarding the ongoing development of IQP-0528 as a vaginally applied agent to prevent the sexual transmission of HIV. Ms. Watson was also an invited participant in a themed discussion entitled "Novel Microbicide Gels and Rings". ImQuest is currently working on the development of IQP-0528 as both a gel and an intravaginal ring product in combination with other highly active microbicide products. These studies included ImQuest coauthors Robert W. Buckheit, Jr., Christa Buckheit, and ImQuest collaborators from The University of Utah.

"These results further define the therapeutic and preventative niche which the pyrimidinediones may fill and their development may not only prevent the transmission of HIV among sexual partners, but may also possess important therapeutic benefits in the context of the inhibition of highly drug resistant virus strains," said Dr. Buckheit. "We are excited to see IQP-0410 enter human clinical trials in 2009."

ImQuest Life Sciences, a privately held U.S. company located in Frederick, Maryland specializes in the preclinical and clinical development of novel compounds for the treatment of infectious disease and cancer. ImQuest BioSciences, also located in Frederick, Maryland, is a leading provider of anti-infective and anti-cancer drug and vaccine development services to the biotechnology and pharmaceutical industry.

    For further information regarding this press release please contact:
    Robert W. Buckheit, Jr., Ph.D.
    Executive Vice President and Chief Scientific Officer
    ImQuest Life Sciences, Inc.

SOURCE ImQuest Life Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ImQuest Awarded SBIR Grant to Define the Mechanism of Action of Their Lead Anti-HIV Therapeutic Compound IQP-0410
2. ImQuest Receives $6.4 M Five Year Award from NIH to Develop Long-Lasting Combination Topical Microbicides To Prevent HIV Transmission
3. ImQuest Presents IND-Enabling Safety Pharmacology and Pharmacokinetic Data for the Therapeutic HIV Compound IQP-0410 at Conference on Retroviruses and Opportunistic Infections
4. Response Genetics Announces Presentations/Webcasts at Upcoming Investor Conferences
5. Juvaris BioTherapeutics Announces Six Scientific Presentations at Infectious Diseases Society of America (IDSA) Meeting October 6, 2007
6. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
7. Actelion Announces Multiple Presentations on Tracleer(R) and the REVEAL Registry at CHEST 2007
8. Response Genetics CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference
9. CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2007
10. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
11. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
Post Your Comments:
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica ... in people with peritoneal or pleural mesothelioma. Their findings are the subject of a ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
Breaking Biology Technology:
(Date:5/12/2016)... 12, 2016 , a brand ... overview results from the Q1 wave of its quarterly ... was consumers, receptivity to a program where they would ... health insurance company. "We were surprised to ... Michael LaColla , CEO of Troubadour Research, "primarily ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: ) ... their customers enhanced security to access and transact ...
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
Breaking Biology News(10 mins):